Skip to main content

Centene vs Elevance Health: Revenue, Profit and Business Model

Centene had $194.8B of annual revenue in FY2025. Elevance Health had $199.1B of annual revenue in FY2025.

Latest financial snapshot

Centene

Latest annual revenue
$194.8B (FY2025)
Net income
Unavailable here
Net margin
—
Revenue growth
+19.0% a year, FY2016–FY2025

Elevance Health

Latest annual revenue
$199.1B (FY2025)
Net income
Unavailable here
Net margin
—
Revenue growth
+9.9% a year, FY2016–FY2025

Financial summary

Centene

Centene's revenue grew from $144.5 billion in 2022 to $194.8 billion in 2025, but profit moved the other way. FY2025 ended with a $6.674 billion GAAP net loss attributable to Centene, compared with $3.3 billion of net income in 2024, after a $6.7 billion non-cash goodwill impairment recorded in Q3 2025; adjusted diluted EPS was $2.08. The turnaround showed up in 2026: Q2 2026 total revenue was $53.6 billion, premium and service revenue was $44.4 billion, GAAP diluted EPS was $2.19 and adjusted diluted EPS was $2.51. Centene raised its 2026 guidance to GAAP diluted EPS above $3.11 and adjusted diluted EPS above $4.80, with premium and service revenue guided to $173-$177 billion. The company does not pay a dividend. Centene Corporation is a colossal managed care enterprise, maintaining a strong market valuation frequently exceeding $40 billion.

Elevance Health

Revenue rose from $171.3B in 2023 to $177.0B in 2024 and $199.1B in 2025, helped by premium-rate increases, acquisitions and Medicare Advantage growth that offset Medicaid attrition. Net income was $5.662B in 2025 on operating income of $7.199B. Growth slowed in 2026 as the company deliberately shrank unprofitable Medicaid, Medicare Advantage and employer risk business: operating revenue was $49.5B in Q1 2026 and $49.8B in Q2 2026. In July 2026 Elevance raised full-year guidance to at least $20.10 GAAP diluted EPS and at least $27.00 adjusted EPS, with operating cash flow of at least $6.0B, and paid a $1.72 quarterly dividend. Elevance Health (formerly Anthem) is a massive American health insurance provider, maintaining a staggering market valuation generally exceeding $120 billion.

Revenue and profit by year

Centene

Centene revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$194.8B——+19.4%Source
FY2024$163.1B——+5.9%Source
FY2023$154B——+6.5%Source
FY2022$144.5B——+14.7%Source
FY2021$126B$1.3B1.1%+13.4%Source
FY2020$111.1B$1.8B1.6%+48.9%Source
FY2019$74.6B$1.3B1.8%+24.2%Source
FY2018$60.1B$900M1.5%+24.3%Source
FY2017$48.4B$828M1.7%+19.1%Source
FY2016$40.6B$562M1.4%—Source
Full Centene financials

Elevance Health

Elevance Health revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$199.1B——+12.5%Source
FY2024$177B——+3.3%Source
FY2023$171.3B——+9.4%Source
FY2022$156.6B$5.9B3.8%+13.0%Source
FY2021$138.6B$6.2B4.4%+13.8%Source
FY2020$121.9B$4.6B3.8%+16.9%Source
FY2019$104.2B$4.8B4.6%+13.1%Source
FY2018$92.1B$3.8B4.1%+2.3%Source
FY2017$90B$3.8B4.3%+6.1%Source
FY2016$84.9B$2.5B2.9%—Source
Full Elevance Health financials

Where the revenue comes from

Centene

  • Medicaid Managed Care

    Core business

    State contracts pay Centene to administer healthcare benefits and coordinate care for Medicaid members.

  • ACA Marketplace Plans

    Major growth and volatility area

    Centene sells health plans on Affordable Care Act exchanges, where subsidy rules, risk adjustment, and medical use drive economics.

  • Medicare Products

    Strategic line

    Medicare Advantage and related products generate premium revenue from CMS and members, with profitability tied to medical costs and star ratings.

  • Commercial and Specialty Services

    Supporting lines

    Other health-plan and service businesses add diversification but remain tied to regulated healthcare economics.

Elevance Health

  • Health Benefits

    About 83% of FY2025 revenue (premiums)

    Commercial, Medicare, Medicaid, BlueCard, FEP, and other insured or administrative health-plan products.

  • CarelonRx

    Pharmacy services

    Pharmacy benefit management and related pharmacy services integrated with Elevance's health-plan base and external customers.

  • Carelon Services

    Health services

    Care delivery, behavioral health, analytics, and other services designed to manage care and cost.

  • Investment Income and Other

    Supplemental

    Investment income and other revenue streams tied to the insurance and services platform.

Business model and strategy

Centene

How it makes money

Centene earns most of its money from premiums paid by governments. State Medicaid agencies pay it a fixed monthly amount per enrolled member to manage that member's care; the federal Centers for Medicare & Medicaid Services (CMS) pays it for Medicare Advantage and Part D drug plans; and ACA Marketplace members pay Ambetter premiums that are largely funded by federal tax credits.

Growth strategy

Under CEO Sarah London, who succeeded Michael Neidorff in 2022, Centene has narrowed its focus to U.S. government-sponsored health plans. It sold non-core assets such as Magellan Rx, its Spanish hospital operator Ribera Salud and UK-based Circle Health, outsourced pharmacy benefit management to Express Scripts, and cut administrative costs.

Competitive advantage

Centene's main advantage is scale and experience in state Medicaid programs. It serves about 12.1 million Medicaid members across 30 states, and every state runs its own procurement, rate-setting and compliance rules.

Centene business model in full

Elevance Health

How it makes money

Elevance makes money in two ways. First, its Health Benefits segment collects premiums from employers, individuals and government programs and pays members' medical claims; profit depends on keeping the benefit expense ratio (89.7% in Q2 2026) below premium levels and on fees for administering self-funded employer plans.

Growth strategy

Elevance is pruning lower-margin business, such as exiting standalone Medicare Part D plans for 2026 and the D.C. Medicaid market, while investing in medical cost management, provider connectivity and Carelon. Recent deals that extend Carelon include BioPlus specialty pharmacy (2023), Kroger Specialty Pharmacy (2024) and CareBridge home-based care (reported at about $2.7B, 2024 to 2025).

Competitive advantage

Elevance's main edge is its Blue Cross Blue Shield licenses in 14 states, which give it dense local provider networks and strong brand recognition with employers, plus access to the national BlueCard network. Owning CarelonRx and Carelon Services lets it keep pharmacy and care-management revenue that rivals without those assets pay to third parties.

Elevance Health business model in full

Questions about Centene vs Elevance Health

Which company has higher revenue — Centene Corporation or Elevance Health, Inc.?

Centene Corporation had $194.8B (FY2025), while Elevance Health, Inc. had $199.1B (FY2025). By latest annual revenue, Elevance Health, Inc. is the larger business, with Centene Corporation showing a smaller revenue base.

What is the market cap of Centene Corporation vs Elevance Health, Inc.?

Centene Corporation's market capitalisation stands at $30.5B, while Elevance Health, Inc.'s is $80.0B. Elevance Health, Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Centene Corporation.

How does revenue per employee compare for Centene Corporation and Elevance Health, Inc.?

Centene Corporation has $3.19M / employee in revenue per employee, while Elevance Health, Inc. has $2.05M / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do Centene Corporation and Elevance Health, Inc. make money?

Centene Corporation and Elevance Health, Inc. generate revenue in fundamentally different ways. Centene Corporation: Centene earns most of its money from premiums paid by governments. Elevance Health, Inc.: Elevance makes money in two ways.

Which company is valued higher relative to revenue — Centene Corporation or Elevance Health, Inc.?

On a price-to-sales (P/S) basis, Centene Corporation trades at 0.2x P/S and Elevance Health, Inc. at 0.4x P/S. Elevance Health, Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Centene Corporation. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is Centene Corporation bigger than Elevance Health, Inc.?

By last reported revenue, Elevance Health, Inc. ($199.1B (FY2025)) is the larger company compared to Centene Corporation ($194.8B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Centene vs Elevance Health overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.